Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Fast Is The Peanut Allergy Treatment Market Expected to Grow Between 2025 And 2029?

The market size for peanut allergy therapies has seen significant expansion of late. Its size is projected to increase from $0.45 billion in 2024 to $0.51 billion in 2025, indicating a compound annual growth rate (CAGR) of 11.4%. The escalation throughout the historical phase can be ascribed to factors such as rising prevalence, progress in diagnostic test technology, the surge of public consciousness and apprehension, the formulation of early intervention tactics, and the reception of regulatory sanctions for peanut allergy treatments.

What Growth Rate Is Anticipated for the Peanut Allergy Treatment Market in the Coming Years?

In the coming years, the market size for peanut allergy treatments is projected to undergo significant expansion. It is forecasted to reach a value of $0.77 billion in 2029, with a compound annual growth rate (CAGR) of 11.1%. Factors contributing to the growth during this forecast period include the ongoing increase in prevalence, the implementation of personalized medicine strategies, the debut of innovative immunotherapy methods, the rise in public and private investments, and the growth of telemedicine services. The forecast period will also see a rise in trends such as enhanced adoption of immunotherapy, advancements in biologic treatment methods, the integration of treatments based on probiotics, technological breakthroughs in delivery systems, strategies focusing on personalized medicine, and regulatory sanctions and backing.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15888&type=smp

Who Are the Leading Companies in the Peanut Allergy Treatment Market?

Major companies operating in the peanut allergy treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Viatris Inc., Regeneron Pharmaceuticals Inc., Hikma Pharmaceuticals plc, ALK-Abelló A/S, Amneal Pharmaceuticals Inc., Amphastar Pharmaceuticals Inc., Stallergenes Greer plc, kaleo Inc., Aquestive Therapeutics Inc., Vedanta Biosciences Inc., Aimmune Therapeutics Inc., AnaptysBio Inc., Alladapt Immunotherapeutics Inc., Aravax Pty Ltd., Intrommune Therapeutics Inc., IgGenix Inc., DBV Technologies SA, Camallergy Ltd., HAL Allergy Group, Prota Therapeutics Pty Ltd.

What Are the Key Drivers of the Peanut Allergy Treatment Market?

The escalation of the peanut allergy treatment market is anticipated due to an increased investment in research and development for allergy treatments. Research and development (R&D) investment, a form of capital dedicated towards innovative activities, product creation, and technology improvements by businesses, organizations, or governments, plays a pivotal role in improving peanut allergy treatments. This investment stimulates the generation of unique immunotherapies and desensitization methodologies, aimed at minimizing allergy responses and enhancing the lifestyle of those suffering from peanut allergies. As an example, the Victorian Government disclosed a tactical $12 million investment in Aravax, a clinical-stage biotech firm based in Australia, in January 2024 to considerably accelerate global peanut allergy treatment. Complementing a broader $66 million round for developing Aravax’s novel immunotherapy, PVX108, this funding has received Phase 2 trial approvals from both the U.S. Food and Drug Administration (FDA) and Australia’s Therapeutic Goods Administration (TGA). This emphasizes its possible worldwide public health contribution. Hence, the research and development investment in allergy treatments is facilitating the expansion of the peanut allergy treatment market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=15888&type=smp

What Are the Key Market Segments in the Peanut Allergy Treatment Industry?

The peanut allergy treatment market covered in this report is segmented –

1) By Drug Class: Antihistamines, Immunotherapies, Epinephrine, Other Drug Classes

2) By Route Of Administration: Injectable, Oral, Other Routes Of Administration

3) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Other Distribution Channels

Subsegments:

1) By Antihistamines: Oral Antihistamines, Topical Antihistamines

2) By Immunotherapies: Oral Immunotherapy (OIT), Sublingual Immunotherapy (SLIT), Epicutaneous Immunotherapy (EPIT)

3) By Epinephrine: Epinephrine Auto-Injectors, Epinephrine Inhalers

4) By Other Drug Classes: Leukotriene Receptor Antagonists, Monoclonal Antibodies, Corticosteroids

What Are the Latest Trends in the Peanut Allergy Treatment Market?

Leading companies in the peanut allergy treatment market are concentrating on the creation of biologic therapies such as anti-IgE monoclonal antibodies, as they seek to offer more precise and powerful solutions for managing peanut allergies, in an effort to enhance patient results and life quality. Anti-IgE monoclonal antibodies are therapeutic agents specifically designed to target and neutralize immunoglobulin E (IgE) antibodies in the human body. For example, Novartis Pharmaceuticals Corporation, a Swiss pharmaceutical firm, received FDA approval for Xolair (omalizumab) in February 2024. This drug aims to mitigate allergic responses, including anaphylaxis, in patients one year and above suffering from IgE-induced food allergies. The approval was granted based on the results from the Phase III OUtMATCH study sponsored by NIH, which demonstrated a noteworthy improvement in food allergy tolerance in patients who were treated with Xolair as opposed to those who received a placebo.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/peanut-allergy-treatment-global-market-report

What Are the Key Regional Markets in the Peanut Allergy Treatment Industry?

North America was the largest region in the peanut allergy treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peanut allergy treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15888

This Report Delivers Insight On:

1. How big is the peanut allergy treatment market, and how is it changing globally?

2. Who are the major companies in the peanut allergy treatment market, and how are they performing?

3. What are the key opportunities and risks in the peanut allergy treatment market right now?

4. Which products or customer segments are growing the most in the peanut allergy treatment market?

5. What factors are helping or slowing down the growth of the peanut allergy treatment market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model